Michele Korfin has over 25 years of experience in the biotech/pharma industry as a Board member and C-level leader. Her areas of expertise are focused on specialized therapies, including those in hematology, oncology, and cell therapy. She has held leadership roles for product launches, clinical development, manufacturing, marketing strategy, commercial sales, business development, investor relations, market access, and government affairs. She has also consulted for private companies seeking guidance on their development path and funding. 

Ms. Korfin sits on the board of Organogenesis, a publicly traded biotech company with a focus on therapies for advanced wound care treatment and sports medicine.

Ms. Korfin was the Chief Operating Officer and Chief Commercial Officer for Gamida Cell.  Ms. Korfin was responsible for leading the operations strategy and execution for Omisirge, the only allogeneic stem cell therapy approved by the U.S. Food and Drug Administration (FDA) on the basis of a global randomized Phase 3 trial.  Ms. Korfin also oversaw Omisirge launch initiatives.  She also provided oversight for the operations and commercial strategy for the Natural Killer Cell platform.

Prior to joining Gamida Cell, Ms. Korfin was the Chief Operating Officer of TYME Technologies. Ms. Korfin’s main focus at TYME was to advance the pivotal clinical trials for pancreatic cancer for SM-88, an oral cancer metabolism-based therapeutic.

Prior to joining TYME, Ms. Korfin was Vice President of Market Access at Kite Pharma, where she oversaw the market access strategy, including payer relations, reimbursement and government affairs for Yescarta®, the first approved CAR-T therapy in lymphoma.

Prior to joining Kite, Ms. Korfin spent more than a decade at Celgene in a variety of key strategic and operational roles, including global marketing, head of the U.S. oncology sales force, U.S. market access lead, Lymphoma marketing lead, and overseeing the global development programs for REVLIMID® in Lymphoma and CLL.

Ms. Korfin has also held prior positions at Merck & Co as a manufacturing scientist, Bain & Company as a consultant and Schering-Plough in sales and marketing.

Ms. Korfin holds a Master in Business Administration from Harvard Business School and a Bachelor of Science degree in Pharmacy from Rutgers University. Ms. Korfin is a licensed pharmacist in New Jersey and is a board member for BioNJ. She resides in New Jersey with her husband, Andy, and their two children, Amanda and Jake.